AE Wealth Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-10,277
Closed -$23K 1468
2020
Q3
$23K Sell
10,277
-120
-1% -$343 ﹤0.01% 1256
2020
Q2
$37K Buy
10,397
+322
+3% +$1.16K ﹤0.01% 1228
2020
Q1
$38K Sell
10,075
-8,592
-46% -$28.3K ﹤0.01% 1075
2019
Q4
$56K Buy
+18,667
New +$48.5K ﹤0.01% 1097

Other funds holding BMY.RT

AE Wealth Management's BMY.RT Position: Q4 2020 in Review

AE Wealth Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q4 2020, closing a stake of 10,277 shares — an estimated $23K sold.

AE Wealth Management first reported a position in BMY.RT in Q4 2019 and held it in 4 quarters. The position peaked at $56K in Q4 2019. 546 funds tracked by Wall St. Rank hold BMY.RT as of Q4 2020.

  • AE Wealth Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q4 2020 after selling out during the quarter.
  • AE Wealth Management sold 10,277 Bristol-Myers Squibb Company Contingent Value Rights shares in Q4 2020, an estimated $23K.
  • AE Wealth Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 4 quarters.
  • AE Wealth Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $56K in Q4 2019.
  • 546 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q4 2020.

Based on AE Wealth Management's 13F filing for Q4 2020, filed 1 Feb 2021.